COVID-19 reminds me of some of the issues with Neuroendocrine Cancer e.g. is this a normal day to day cold/flu/chest issue or is it COVID-19? At least COVID-19 is the number one awareness topic in the universe so people are very very aware. Just as well because it has the potential to kill hundreds of […]
NEW CONTENT added 28 March 2020: See below for NET Specialist video regarding all issues with treatment and surveillance OPINION. My third article on the COVID-19 issue and based on the top topic currently in my private group – treatment and surveillance concerns over the period of COVID-19 restrictions. I have no answers, sorry. My […]
OPINION. I guess many people are feeling pretty scared right now. Add age, a chronic disease, cancer, a lung illness or any condition that has a level of immunosuppression, and it seems to become even more scarier when you read the news. I think the ‘not knowing’ how this crisis is going to pan out […]
This is not medical advice. UPDATED 24 Mar 2020– some questions specifically related to NETs were added – output from Dr Pamela Kunz Oncology and NET Specialist) and Dr. Janice (Wes) Brown (Infectious Disease). At least one question answered by Dr Jame Howe (Surgeon). See Article 4 below. UPDATED 21 Mar 2020 – excellent Q&A […]
Nutrition is an important subject for many cancers but it is particularly important for Neuroendocrine Cancer. In the previous parts of this series I focused on the following: Article 1 – Vitamin and Mineral Challenges. This was co-authored by Tara Whyand, UK’s most experienced NET Specialist Dietitian. This blog provides a list of vitamins and minerals which […]
Excellent news for those who don’t have Gastroenteropancreatic NETs (GEP-NETs). A trial of PRRT is being set-up for the less common types of NET incuding those with an unknown primary. Using the DOTATOC radionuclide rather then the Lutathera model of using DOTATATE, this trial will cater for Pulmonary, Pheochromoctyoma, Paraganlioma, Unknown Primary and Thymic Neuroendocrine […]
Rani Therapeutics, a leader in oral biologics, has announced positive results from the Phase I clinical study of its orally-delivered version of octreotide, Octreotide-RP, a drug used in the treatment of acromegaly and neuroendocrine tumors. The Phase I study successfully achieved both its primary and secondary endpoints, demonstrating the safety and tolerability of Octreotide-RP, the […]
As featured by Neuroendocrine Cancer UK (formerly NET Patient Foundation) It’s well known that Neuroendocrine Cancer can often be a difficult to diagnose condition. However, what is less well known is the impact it has on those who are diagnosed. I’m one of the lucky ones, even though I still ended up with distant metastases. […]
[…] Ronny’s latest post – BREAKING NEWS – US FDA Approves Lutetium Lu 177 dotatate (Lutathera®) – PRRT? […]
Positive Reinforcement – Required Treatment
https://polldaddy.com/js/rating/rating.js
😊
Excellent research Ronny. Getting a global view of the current status will be very helpful to any folks unable to receive the PRRT in their homeland.
Big Thankyou for your continued efforts and sharing data as you receive it!!!
https://polldaddy.com/js/rating/rating.js